Cavaliere R, Di Filippo F, Santori F S, Piarulli L, Carlini S, Calabrò A, Pagliarin M, Cavaliere F, Cerulli P, Monticelli G
Oncology. 1987;44(1):1-5. doi: 10.1159/000226433.
The role of hyperthermic perfusion (HP) for the treatment of limb osteogenic sarcoma was evaluated in 76 patients. Twelve patients were treated with HP alone, and a 5- and 10-year survival rate of 25.5% was obtained. When amputation was systematically associated to HP (12 patients), a 5- and 10-year survival rate of 50.9% was achieved. Twenty-seven patients were treated with hyperthermic antiblastic perfusion (HAP) followed by amputation 4 weeks later. With this treatment, the 5- and 10-year actuarial rates rose to 71.4 and 65%, respectively, with a 5-year disease-free survival rate of 67.4%. Fifteen patients were treated with HAP followed by an 'en bloc' resection and bone reconstruction. The 5- and 10-year actuarial survival rate obtained was 63.5% with a 5-year disease-free survival rate of 53.6%. These results seem to indicate that HAP permits carrying out conservative rather than ablative surgery for the treatment of limb osteogenic sarcoma.
对76例肢体骨肉瘤患者评估了热灌注（HP）治疗的作用。12例患者仅接受热灌注治疗，5年和10年生存率为25.5%。当热灌注系统性联合截肢时（12例患者），5年和10年生存率达到50.9%。27例患者接受热化疗灌注（HAP）治疗，4周后行截肢术。采用这种治疗方法，5年和10年精算生存率分别升至71.4%和65%，5年无病生存率为67.4%。15例患者接受热化疗灌注后行“整块”切除及骨重建。获得的5年和10年精算生存率为63.5%，5年无病生存率为53.6%。这些结果似乎表明，热化疗灌注允许对肢体骨肉瘤进行保肢手术而非截肢手术。
